Skip to Content
  • The Singularity, Postponed

    I’ve had some problems over the years with the Singularity-Is-Near line of thought, and some problems with the “If we can build a new generations of… Read More
  • Gilenya’s Price

    A couple of weeks ago, we had this discussion about the cost-effectiveness of drugs for multiple sclerosis. It was pointed out that Novartis’s new Gilenya… Read More
  • Cladribine Is Gone

    Multiple sclerosis therapy has been changing a lot in recent years, and one of the biggest events was the introduction of Gilenya (fingolimod). That’s the… Read More
  • The NIH Goes For the Gusto

    Here’s an interesting funding opportunity from NIH: Recent advances in neuroscience offer unprecedented opportunities to discover new treatments for nervo… Read More
  • New Cures! Faster! Faster!

    I wrote here the other day about the NIH’s new translational medicine plans. The New York Times article that brought this to wide attention didn’t g… Read More
  • Fanapt: Not Paying Out

    Poker players in the audience may remember the old story of the guy who lost three cars over the years by drawing to try to fill inside straights – the fi… Read More
Page 10 of 17« First...89101112...Last »